Dignitana AB has signed Science International Corporation to launch The DigniCap Scalp Cooling System in Hong Kong and Macao. Science International now becomes the exclusive provider of DigniCap in Hong Kong and Macau to minimize hair loss from chemotherapy. The company has already purchased two DigniCap Delta devices to introduce DigniCap's clinically superior solution to the region.

The DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, ovarian and prostate cancer. With just approximately 8 million residents in the region, breast cancer is the most common cancer among females in Hong Kong, representng 27% of all new cancers in females diagnosed in Hong Kong in 2019. Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network® (NCCN) and Cancer Australia.

FDA-cleared DigniCap is available in it's primary US market and in cancer centers around the globe.